Congenital Chylothorax in a Late Preterm Infant and Successful Treatment With Octreotide  by Foo, Ning-Hui et al.
Pediatrics and Neonatology (2011) 52, 297e301ava i lab le at www.sc iencedi rec t .com
journa l homepage: ht tp : / /www.pedia t r -neonato l . comCASE REPORT
Congenital Chylothorax in a Late Preterm Infant
and Successful Treatment With OctreotideNing-Hui Foo a, Yea-Shwu Hwang b, Chin-Chuan Lin c, Wen-Hui Tsai a,d,*aDepartment of Pediatrics, Chi Mei Foundation Hospital, Tainan, Taiwan
bDepartment of Occupational Therapy, College of Medicine, National Cheng Kung University, Tainan, Taiwan
cDepartment of Obstetrics and Gynecology, Chi Mei Foundation Hospital, Tainan, Taiwan
d Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan





somatostatin analog* Corresponding author. Departme
Foundation Hospital, 901 Chung-Hwa
Tainan 710, Taiwan.
E-mail address: briants@ms19.hine
1875-9572/$36 Copyright ª 2011, Taiw
doi:10.1016/j.pedneo.2011.06.011Chylothorax is defined as abnormal accumulation of lymphatic fluid in the pleural space and is
a rare condition in neonates. Chylothorax causes respiratory and nutritional problems and
a significant mortality rate. Octreotide is a long-acting somatostatin analog that can reduce
lymphatic fluid production and has been used as a new strategy in the treatment of chylothor-
ax. Here, we report a premature baby with severe bilateral pleural effusion diagnosed by
prenatal ultrasound and subsequently confirmed to be congenital chylothorax after birth. This
newborn baby was initially treated with bilateral chest tube insertion to relieve severe respi-
ratory distress. However, the chylothorax recurred after a medium-chain-triglyceride-enriched
formula was initiated. The accumulation of chylothorax diminished after the administration of
octreotide. Therefore, octreotide may allow the patient to avoid invasive procedures, such as
reinsertion of chest tubes or surgery.
Copyright ª 2011, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Chylothorax is defined as abnormal accumulation of
lymphatic fluid in the pleural space and is a relatively rarent of Pediatrics, Chi Mei
Road, Yung-Kang District,
t.net (W.-H. Tsai).
an Pediatric Association. Publishcondition in newborns. In neonates, chylothorax occurs in
situations causing damage to the thoracic duct, such as
cardiothoracic surgery, birth trauma, and great vessel
thrombosis.1 It also occurs in dysmorphic syndromes, such
as Turner or Noonan syndrome. However, in many situa-
tions, the etiology of the chylothorax is uncertain and is
believed to be caused by abnormality of thoracic or
pulmonary lymphatic system. This is termed idiopathic
congenital chylothorax.2 Regardless of the underlying
mechanism, chylothorax causes respiratory, nutritional,ed by Elsevier Taiwan LLC. All rights reserved.
Figure 2 X-ray picture showing the presence of bilateral
large amounts of pleural effusion, ascites (centralized bowel
loops), and subcutaneous edema.
298 N.-H. Foo et aland immunological complications.3,4 The mortality rate has
been reported to be as high as 50% depending on gesta-
tional age, presence of abnormal karyotype, additional
congenital anomalies, hydrops fetalis, and the duration and
severity of the chylothorax.3
Octreotide is a long-acting somatostatin analog that acts
on somatostatin receptors in the splanchnic vessels to
inhibit lymphatic fluid production. Octreotide has been
used in the treatment of postoperative or spontaneous
chylothorax in infants and older children.5,6 It has also been
used for the treatment of congenital chylothorax in term
neonates.7,8 However, the experience of octreotide use in
premature babies with congenital chylothorax is
limited.6,9e14
Here, we report a female premature baby identified
with prenatal severe bilateral pleural effusion and subse-
quently diagnosed with congenital chylothorax after
delivery. She was initially treated with emergent chest tube
insertion because of severe respiratory distress and was
successfully treated with octreotide when the chylothorax
reaccumulated. Octreotide avoided the baby needing
reinsertion of the chest tube or surgery.
2. Case Report
This female neonate was delivered at 35 weeks of gestation
to a primigravida mother by means of cesarean delivery for
severe bilateral pleural effusion. The birth weight was
1904 g, and the Apgar scores were 1 at 1 minute and 4 at
5 minutes. The parents were nonconsanguineous, and the
pregnancy was uneventful until 2 days before the delivery,
when bilateral severe pleural effusion was detected by
routine prenatal ultrasound (Figure 1). After delivery, the
neonate was intubated because of severe respiratory
distress and admitted to the neonatal intensive care unit.
The patient had generalized edema but no dysmorphic
features. A chest X-ray revealed severe bilateral whiteout
of the lung field (Figure 2), and bilateral pleural effusion
was confirmed by ultrasound.
Bilateral chest tube insertion was performed immedi-
ately because of severe respiratory distress and deteriora-
tion of O2 saturation. The drained pleural effusion revealedFigure 1 Prenatal ultrasound demonstrating the presence of
bilateral large amount of pleural effusion.straw-colored fluid. The cell counts of the pleural effusion
revealed the following: red blood cells, 1750 cells/mm3 and
white blood cells (WBCs), 1950 cells/mm3 with 100%
lymphocytes. Biochemical analysis of the pleural effusion
revealed the following: glucose, 54 mg/dL; total protein,
3.1 g/dL; lactate dehydrogenase, 97 IU/L; total choles-
terol, 17 mg/dL; and triglyceride, 10 mg/dL (before
feeding). The cell counts of the peripheral blood revealed
the following: WBC, 12,300 cells/mm3 with 42% neutrophils
and 30% lymphocytes (absolute lymphocyte count,
3690 cells/mm3). The albumin level of the plasma was
2.0 g/dL. Total parenteral nutrition (TPN) was initiated.
Follow-up chest X-ray and ultrasound revealed no pleural
effusion accumulation. On Day 4, the endotracheal tube
was removed, and feeding was initiated. To observe the
change of triglyceride level after feeding but avoid wors-
ening of the chylothorax, we started a small amount of
feeding with 2 mL of half-strength regular formula every
12 hours. The output of pleural effusion continued to
decrease, but the color became turbid. The cell counts of
the pleural effusion revealed the following: red blood cells,
4300 cells/mm3 and WBC, 7029 cells/mm3 with 66%
lymphocytes and 34% neutrophils, and the biochemical
analysis revealed the following: total cholesterol, 28 mg/dL
and triglyceride, 170 mg/dL. The cell counts of the
peripheral blood revealed the following: WBC, 9300 cells/
mm3 with 69% neutrophils and 10% lymphocytes (absolute
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tubes were removed on Day 10 and Day 18, respectively,
because of malfunction. Enteral feedings with a medium-
chain-triglyceride (MCT)-enriched formula (Alfare; Nestle,
Vevey, Switzerland) were initiated on Day 15.
After the removal of the chest tubes, ultrasound was
performed daily, and no reaccumulation of pleural effusion
was detectable till Day 20. On Day 21, minimal pleural
effusion was detected by ultrasound on the right side, and
by Day 23, the pleural effusion thickness reached 9 mm,
measured by ultrasound. There was also gradual respiratory
deterioration. Instead of reinsertion of chest tubes or
surgery, we decided to try octreotide. It was started at
a beginning dose of 16 ug/kg/d subcutaneously in two
divided doses and gradually increased to 48 ug/kg/d, and
a 7-day course was completed. After the commencement of
octreotide, right-side pleural effusion gradually subsided,
along with respiratory improvement. By Day 33, the pleural
effusion was no longer detectable by ultrasound. The
relationship among amount of pleural effusion, nutrition
types, and octreotide use is summarized in Figure 3. No side
effects of octreotide, such as nausea, vomiting, diarrhea,
hyperglycemia, hypotension, or liver dysfunction, were
observed during the period of treatment. No reac-
cumulation of pleural effusion was detected thereafter.
The chromosome analysis revealed normal female
karyotype.3. Discussion
The strategy of treating chylothorax is the same regardless
of the etiology of chylothorax. The first step is aspiration of
the pleural fluid for initial drainage and diagnostic purpose.
However, continuous drainage of the chyle with a chest
tube is indicated if the effusion causes respiratory distress
or the accumulation of effusion recurs.5 Chest tube may be
required for a period of time because it takes time for chyle
leakage to heal. However, long-term insertion of chest tube
has been reported to be associated with hypoproteinemia,Figure 3 Graph showing the amount of pleural effusion, nutritio
both chest tubes had been removed, the amount of right-side ple
intercostal space at the posterior axillary line. No pleural effusion
MCTZmedium-chain triglyceride.lymphopenia, hypogammaglobulinemia, infection, and
prolonged ventilator use and its associated lung injury,
leading to prolonged hospitalization and emotional stress to
the family.2,4
Nutritional support in the management of chylothorax is
aimed at providing adequate caloric intake while mini-
mizing the chyle flow in the thoracic duct to wait for
spontaneous healing of the leakage site. This is usually
achieved by feeding with a formula high in MCT, which
bypasses the intestinal lymphatic system and is absorbed
directly to the portal vein.15 It is noteworthy that even
water intake by mouth can produce thoracic lymph
flow,16,17 and a formula containing MCT with up to 87% of
fat can also cause reaccumulation of pleural effusion.3
Therefore, complete enteric rest using TPN is suggested
by some authors.18,19 A practical approach is to use TPN
until the output of pleural effusion is minimal and the
cardiopulmonary status is stable. Then, a trial of feeding
with MCT-enriched formula can be given with close moni-
toring of reaccumulation of pleural effusion, either by
chest tube drainage or ultrasound.3
Surgical interventions of chylothorax, including direct
ligation of the thoracic duct, pleural abrasion, pleurodesis,
or pleural-to-peritoneal shunts, should be considered if
medical treatment fails to decrease chyle flow and allow
healing of the thoracic duct. The timing of surgery is not
uniformly defined. Most authors suggest at least 3e5 weeks
of medical therapy before proceeding to surgery.2,20,21
However, if a chyle-leaking site could be well identified
and the flow is high, which makes spontaneous healing less
likely, early surgery is suggested.22 Successful surgery
shortens the duration of chest tube insertion and, thus,
reduces the risks of its complications and shortens the
duration of hospitalization.
In this case, left and right chest tubes were removed on
10 days and 18 days of life, respectively, because of
obstruction of the chest tube. When the chylothorax reac-
cumulated and the patient had significant respiratory
distress, instead of reinsertion of chest tubes or surgery, we
decided to try octreotide. After treatment with octreotide,n types, and octreotide infusion duration. After Day 20, when
ural effusion was detected by ultrasound through the eighth
accumulation was detectable by ultrasound on the left side.
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bility that the improvement of chylothorax was because of
natural history of the disease. However, we measured the
accumulation of chyle by ultrasound daily, and the
improvement of the chylothorax coincided with the initia-
tion of octreotide; it is likely that the subsiding of pleural
effusion was because of octreotide treatment.
Somatostatin is a polypeptide secreted from the para-
ventricular nucleus of the hypothalamus. It has an inhibi-
tory effect on the secretion of growth hormone, glucagon,
and insulin. Octreotide, a synthetic somatostatin analog, is
more potent in inhibiting endocrine system and has a much
longer half-life. In gastrointestinal tract, somatostatin and
octreotide act on somatostatin receptors to reduce intes-
tinal blood flow by vasoconstriction of the splanchnic
vessels; decrease gastrointestinal motility; and inhibit
gastric, pancreatic, and biliary secretions, thus reducing
intestinal fat absorption and lymphatic flow in the thoracic
duct.6,23e26 Somatostatin and octreotide have been used
to treat a variety of diseases, including acromegaly,
carcinoid syndrome, secretory diarrhea, severe gastroin-
testinal bleeding, postgastrectomy dumping syndrome,
chemotherapy-induced diarrhea, and persistent hyper-
insulinemic hypoglycemia.27e30 Octreotide has been used in
the treatment of postoperative or spontaneous chylothorax
in infants and older children.5,6 It has also been used for the
treatment of congenital chylothorax in term neonates.7,8
The experience of octreotide use in premature babies
with congenital chylothorax is limited.6,9e14 There is no
consensus on the route, dosage, and duration of octreotide
administration for chylothorax. It could be administered as
a continuous intravenous infusion or given twice daily as an
intravenous bolus or subcutaneously. The effective daily
doses were from 7.2 ug/kg to 240 ug/kg (median, 68 ug/kg)
for intravenous infusion and from 2 ug/kg to 68 ug/kg
(median, 40 ug/kg) for subcutaneous administration. The
duration of administration ranged from 3 days to 43 days.6
We started subcutaneous octreotide at a lower dose of
16 ug/kg/d for safety reason and reached a final dose of
48 ug/kg/d.
Octreotide is generally considered to be safe, with only
occasional side effects. The side effects of octreotide are
mainly related to its vasoconstrictive and antisecretory
actions. The reported adverse reactions include cramps,
flatulence, nausea, diarrhea, necrotizing enterocolitis,
hyperglycemia, transient hypothyroidism, and liver
dysfunction.6,26 No aforementioned side effects of octreo-
tide were observed in our patient.
In conclusion, octreotide in the treatment of a prema-
ture baby with congenital chylothorax appears to be a safe
and effective adjunct therapy. It prevented our patient
from undergoing reinsertion of chest tubes or surgery.
However, further studies in a larger number of patients are
required to determine the effectiveness, proper dosing,
and side effects of this drug in the treatment of congenital
chylothorax.References
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